Ashland Inc. (ASH) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended December 31, 2025 (Fiscal Q1 2026). Ashland Inc. is a global additives and specialty ingredients company operating through four reportable segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. The company is a large accelerated filer with approximately 2,900 employees serving customers in over 100 countries.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Sales | $386 million | $405 million |
| Gross Profit | $105 million (27.2% margin) | $111 million (27.4% margin) |
| Operating Loss | $(6) million | $(179) million |
| Net Loss | $(12) million | $(165) million |
| Diluted EPS (Net Loss) | $(0.26) | $(3.50) |
| EBITDA | $40 million | $(129) million |
| Adjusted EBITDA | $58 million | $61 million |
| Operating Cash Flow | $125 million | $(30) million |
| Free Cash Flow | $111 million | $(53) million |
| Cash and Equivalents | $304 million | $215 million (Sep 30, 2025) |
| Long-Term Debt | $1,387 million | $1,384 million (Sep 30, 2025) |
Material Changes vs. Prior Period
- Significant Improvement in Net Loss: The net loss narrowed significantly from $165 million in Q1 2025 to $12 million in Q1 2026. This improvement is primarily due to the absence of a $183 million impairment charge related to the Avoca business divestiture that impacted the prior year period.
- Sales Decline: Sales decreased by $19 million (4.7%) year-over-year, driven by lower volume, the impact of the Avoca business sale ($10 million), and unfavorable pricing/mix, partially offset by favorable foreign currency exchange.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by $8 million to $86 million, largely due to $10 million in environmental-related expenses and $4 million in restructuring costs.
- Cash Flow Surge: Operating cash flow turned positive at $125 million, a $155 million improvement from the prior year, driven by favorable working capital changes and a $103 million federal tax refund.
Guidance, Outlook, and Risks
- Updated Guidance: Ashland narrowed its full-year fiscal 2026 Adjusted EBITDA guidance to $400 million to $420 million (previously $400M-$430M). This reflects approximately $11 million of temporary impacts from a Calvert City startup delay and weather-related disruptions in Q2.
- Outlook: Management expects double-digit plus growth in Adjusted Diluted EPS excluding intangibles amortization. Core end markets in Personal Care and Life Sciences remain resilient, while Specialty Additives and Intermediates markets are mixed.
- Restructuring: The company is executing a multi-year manufacturing network optimization expected to generate $50M-$55M in pre-tax savings. A $30 million restructuring plan initiated in fiscal 2025 continues into fiscal 2026.
- Risks: Key risks include ongoing asbestos litigation (reserves of $418 million total for Ashland and Hercules), environmental remediation liabilities ($226 million reserve), geopolitical instability, and tariff-related uncertainty.
Investor Verification Checklist
- Asbestos and Environmental Reserves: Verify the adequacy of the $418 million asbestos litigation reserve and $226 million environmental remediation reserve, noting the reliance on actuarial models and insurance recoveries.
- Non-GAAP Reconciliations: Review the reconciliation of Adjusted EBITDA ($58M) to Net Loss ($12M) to understand the impact of key items like environmental adjustments and restructuring costs.
- Divestiture Impacts: Confirm the full financial impact of the Avoca business sale completed in March 2025 on future revenue streams and segment performance.
- Debt Covenants: Monitor the consolidated net leverage ratio (currently 2.7x vs. 4.0x limit) and interest coverage ratio (6.5x vs. 3.0x limit) to ensure continued compliance.
- Calvert City Startup: Track the resolution of the startup delay and weather disruptions mentioned in the guidance update to assess Q2 recovery potential.